# A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors

> **NCT07016490** · PHASE1 · RECRUITING · sponsor: **Shenyang Sunshine Pharmaceutical Co., LTD.** · enrollment: 15 (estimated)

## Conditions studied

- Advanced Malignant Tumors

## Interventions

- **DRUG:** SSGJ-709

## Key facts

- **NCT ID:** NCT07016490
- **Lead sponsor:** Shenyang Sunshine Pharmaceutical Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-12
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-01-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07016490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07016490, "A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07016490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*